Imatinib (Gleevec) can bind to the catalytic site of ATK, thereby blocking the enzyme’s ability to phosphorylate targets, thus being useful in the initial treatment of CML [35]. Here, BTK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.